BioPharmSignal logoBioPharmSignal

Biotech News

89bio to Participate in Goldman Sachs 46th Annual Global Healthcare Conference

89bio, Inc. (ETNB)89bio, Inc.Conference / presentation

SAN FRANCISCO, June 04, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that

Open original release

Related news

MLYSMineralys Therapeutics2026-06-08 20:05 EST

Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

CVRXCVRx2026-05-27 20:30 EST

CVRx to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

MLYSMineralys Therapeutics2026-05-27 12:00 EST

Mineralys Therapeutics to Participate in the Jefferies Global Healthcare Conference

MNKDMannKind2026-02-19 14:00 EST

MannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

EMBCEmbecta2025-12-18 22:00 EST

embecta to Participate at the J.P. Morgan 2026 Healthcare Conference

ETNB89bio, Inc.2025-08-28 20:05 EST

89bio to Participate in Upcoming Investor Conferences

CVRXCVRx2026-05-20 20:30 EST

CVRx to Present at the William Blair 46th Annual Growth Stock Conference

MISTMilestone Pharmaceuticals Inc.2026-02-26 13:00 EST

Milestone® Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference

MNKDMannKind2026-05-27 20:00 EST

MannKind to Present at Jefferies Global Healthcare Conference

EMBCEmbecta2026-05-08 13:00 EST

embecta to Participate at the 2026 BofA Securities Global Health Care Conference

View all latest news

89bio, Inc.

89bio is a liver and metabolic disease company focused on MASH and related liver biology. Its story is driven by the possibility of creating a major liver-disease franchise.

Recent company news

ETNB89bio, Inc.2025-09-18 05:02 EST

89bio, Inc. Announces Agreement to be Acquired by Roche

ETNB89bio, Inc.2025-09-05 20:05 EST

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ETNB89bio, Inc.2025-08-28 20:05 EST

89bio to Participate in Upcoming Investor Conferences

ETNB89bio, Inc.2025-08-07 20:06 EST

89bio Reports Second Quarter 2025 Financial Results and Corporate Updates

ETNB89bio, Inc.2025-08-04 20:05 EST

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States